NAALAD2

mass-spec protein & survival
Survivalmass-specKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, NAALAD2 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated NAALAD2 data layer compared with 28 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher NAALAD2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated NAALAD2 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC are the cancer types where NAALAD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
PDACDFSQuartileII,III,IV0.7880.234.0246view →
Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

NAALAD2–PDAC (DFS)

Kaplan–Meier survival curve for NAALAD2 mass-spec protein-high vs -low samples in PDAC.

Open the PDAC breakdown →

Exploration